Oslo, Norway, 10 September 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces an Investor Science and Strategy Forum to be held in Oslo on Wednesday 17 September 2025 at 11:30am CET. Attendance by registration only. The format will be a panel discussion and open questions and answers (Q&A). The panel will include: Dr. Namir Hassan, CEO, Zelluna ASA, Moderator Prof. Bent Jakobsen, Pioneer of T ...